| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 1,120 | 1,376 | ||
| Short-term investments | 4,765 | 3,067 | ||
| Accounts receivable and other receivables, net of allowance for credit losses of 559 and 0 as of september 30, 2025 and december 31, 2024, respectively | 831 | 1,264 | ||
| Inventories | 1,457 | 1,489 | ||
| Note receivable - current, net of allowance for credit losses (note 7) | 0 | 0 | ||
| Prepaid expenses and other current assets | 214 | 383 | ||
| Current assets of discontinued operations - goodwheat | 0 | 0 | ||
| Total current assets | 8,387 | 7,579 | ||
| Property and equipment, net | 10 | 12 | ||
| Right of use asset | 0 | 10 | ||
| Intangible assets, net | 39 | 39 | ||
| Note receivable - noncurrent, net of allowance for credit losses (note 7) | 0 | 0 | ||
| Other noncurrent assets | 148 | 148 | ||
| Total assets | 8,584 | 7,788 | ||
| Accounts payable and accrued expenses | 2,015 | 1,558 | ||
| Other current liabilities-Related Party | 0 | 0 | ||
| Operating lease liability current | 0 | 11 | ||
| Other current liabilities-Nonrelated Party | 270 | 270 | ||
| Total current liabilities | 2,285 | 1,839 | ||
| Common stock warrant and option liabilities | 856 | 1,416 | ||
| Other noncurrent liabilities | 0 | 0 | ||
| Total liabilities | 3,141 | 3,255 | ||
| Common stock, 0.001 par value - 150,000,000 shares authorized as of september 30, 2025 and december 31, 2024 1,367,429 and 1,364,940 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 65 | - | ||
| Additional paid-in capital | 285,259 | - | ||
| Accumulated deficit | -279,881 | - | ||
| Total stockholders' equity | 5,443 | 4,533 | ||
| Total liabilities and stockholders equity | 8,584 | 7,788 | ||
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)